切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2018, Vol. 12 ›› Issue (03) : 129 -134. doi: 10.3877/cma.j.issn.1674-0785.2018.03.001

所属专题: 文献

临床研究

阿托伐他汀对2型糖尿病患者颈动脉粥样硬化的作用
吴艳1, 张怀国1,(), 梁存福1, 徐向文1, 范海影1, 陶蕊1, 王玲玲1, 李斌1, 李树法1   
  1. 1. 276003 山东临沂,临沂市人民医院全科医学科
  • 收稿日期:2017-09-07 出版日期:2018-02-01
  • 通信作者: 张怀国
  • 基金资助:
    山东省自然科学基金(ZR2014HP026,ZR2014HL029); 临沂市科技发展计划项目(201313027)

Effect of atorvastatin intervention on carotid atherosclerosis in patients with type 2 diabetes mellitus

Yan Wu1, Huaiguo Zhang1,(), Cunfu Liang1, Xiangwen Xu1, Haiying Fan1, Rui Tao1, Lingling Wang1, Bin Li1, Shufa Li1   

  1. 1. Department of General Practice, Linyi People′s Hospital, Linyi 276003, China
  • Received:2017-09-07 Published:2018-02-01
  • Corresponding author: Huaiguo Zhang
  • About author:
    Corresponding author: Zhang Huaiguo, Email:
引用本文:

吴艳, 张怀国, 梁存福, 徐向文, 范海影, 陶蕊, 王玲玲, 李斌, 李树法. 阿托伐他汀对2型糖尿病患者颈动脉粥样硬化的作用[J/OL]. 中华临床医师杂志(电子版), 2018, 12(03): 129-134.

Yan Wu, Huaiguo Zhang, Cunfu Liang, Xiangwen Xu, Haiying Fan, Rui Tao, Lingling Wang, Bin Li, Shufa Li. Effect of atorvastatin intervention on carotid atherosclerosis in patients with type 2 diabetes mellitus[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(03): 129-134.

目的

探讨阿托伐他汀治疗对2型糖尿病患者糖代谢、脂代谢、炎症因子水平及颈动脉粥样硬化的作用。

方法

选取临沂市人民医院2015年1月至2016年12月收治的2型糖尿病患者196例,按治疗方式的不同随机分为对照组与阿托伐他汀组,各98例。2组患者均予降糖、降压及阿司匹林治疗,阿托伐他汀组在此基础上加用阿托伐他汀20 mg治疗,均持续治疗6个月。采用t检验比较2组患者治疗前后糖代谢指标[空腹血糖(FPG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)]、脂代谢[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、炎症因子[C反应蛋白(CRP)、白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)、细胞间黏附分子-1(ICAM-1)、血管细胞黏附分子-1(VCAM-1)、内皮细胞选择蛋白(Selectin)]水平及颈动脉粥样硬化指标[颈动脉内中膜厚度(IMT)、斑块厚度、斑块大小、斑块数量)的差异,采用Logistic回归分析分析IMT的影响因素。

结果

治疗后,阿托伐他汀组的糖代谢指标FPG、HbA1c、FINS、HOMA-IR水平与对照组相比差异均无统计学意义[(6.42±1.21)mmol/L vs(6.27±1.05)mmol/L,t=0.406,P=0.572;(6.21±0.65)% vs(6.08±0.73)%,t=0.662,P=0.339;(13.04±1.21)% vs(12.83±1.15)%,t=0.316,P=0.606;(3.75±0.27) vs(3.64±0.35),t=0.283,P=0.692)];脂代谢指标TC、TG、LDL-C的水平低于对照组,HDL-C的水平高于对照组,差异具有统计学意义[(3.18±0.33) vs(4.76±0.39),t=2.738,P=0.009;(1.69±0.14) vs(2.13±0.31),t=3.012,P=0.003;(1.74±0.27) vs(3.08±0.39),t=3.974,P=0.001;(1.26±0.21) vs(1.04±0.15),t=2.458,P=0.014)];炎症因子CRP、IL-6、TNF-α、ICAM-1、VCAM-1、Selectin的水平低于对照组,差异具有统计学意义[(0.83±0.09) vs(0.92±0.11),t=2.576,P=0.036;(1.83±0.25) vs(2.32±0.36),t=3.119,P=0.025;(33.83±4.15) vs(41.92±6.11),t=3.102,P=0.029;(198.83±14.15) vs(210.92±15.11),t=2.583,P=0.035;(457.83±41.15) vs(501.92±38.11),t=2.104,P=0.043;(20.04±1.91) vs(25.83±2.09),t=2.722,P=0.031)];颈动脉粥样硬化指标IMT、斑块厚度、斑块大小、斑块数量低于对照组差异具有统计学意义[(1.05±0.12)mm vs(1.30±0.16)mm,t=3.501,P=0.012;(2.64±0.37)mm vs(3.23±0.55)mm,t=3.164,P=0.019;(0.078±0.021)cm2 vs(0.093±0.025)cm2t=4.068,P=0.001;(3.54±0.62)个vs(4.23±0.92)个,t=2.083,P=0.042]。服用阿托伐他汀和HDL-C水平是IMT的保护因素,TC、TG、LDL、CRP、IL-6和TNF-α水平是IMT的危险因素。

结论

阿托伐他汀治疗可有效调节2型糖尿病患者的脂代谢,降低炎症反应和颈动脉粥样硬化。

Objective

To investigate the effect of atorvastatin intervention on glucose and lipid metabolism, inflammatory cytokine levels, and carotid atherosclerosis in patients with type 2 diabetes mellitus.

Methods

A total of 196 patients with type 2 diabetes mellitus treated at our hospital between January 2015 and December 2016 were collected and divided into either a control group (n=98) or an atorvastatin group (n=98) according to treatment method. The patients in both groups were treated with basic treatment, and the patients in the atorvastatin group were additionally treated with atorvastatin. The changes of glucose metabolism, lipid metabolism, inflammatory cytokine levels, and carotid artery atherosclerosis-related indexes were analyzed and compared between the two groups.

Results

After treatment, FPG, HbA1c, INS, and HOMA-IR levels were not statistically significant between the two groups of patients [(6.42±1.21) mmol/L vs (6.27±1.05) mmol/L, t=0.406, P=0.572; (6.21±0.65)% vs (6.08±0.73)%, t=0.662, P=0.339; (13.04±1.21)% vs (12.83±1.15)%, t=0.316, P=0.606; (3.75±0.27) vs (3.64±0.35), t=0.283, P=0.692), respectively]. TC, TG, and LDL-C were significantly lower and HDL-C was significantly higher in the atorvastatin group than in the control group [(3.18±0.33) vs (4.76±0.39), t=2.738, P=0.009; (1.69±0.14) vs (2.13±0.31), t=3.012, P=0.003; (1.74±0.27) vs (3.08±0.39), t=3.974, P=0.001; (1.26±0.21) vs (1.04±0.15), t=2.458, P=0.014), respectively]. CRP, IL-6, TNF-α, ICAM-1, VCAM-1, and Selectin levels were significantly lower in the atorvastatin group than in the control group [(0.83±0.09) vs (0.92±0.11), t=2.576, P=0.036; (1.83±0.25) vs (2.32±0.36), t=3.119, P=0.025; (33.83±4.15) vs (41.92±6.11), t=3.102, P=0.029; (198.83±14.15) vs (210.92±15.11), t=2.583, P=0.035; (457.83±41.15) vs (501.92±38.11), t=2.104, P=0.043; (20.04±1.91) vs (25.83±2.09), t=2.722, P=0.031), respectively]. IMT, plaque thickness, plaque size, and plaque number were significantly lower in the atorvastatin group than in the control group [(1.05±0.12) mm vs (1.30±0.16) mm, t=3.501, P=0.012; (2.64±0.37) mm vs (3.23±0.55) mm, t=3.164, P=0.019; (0.078±0.021) cm2 vs (0.093±0.025) cm2, t=4.068, P=0.001; (3.54±0.62) vs (4.23±0.92), t=2.083, P=0.042, respectively]. In multivariate logistic regression analysis, IMT was significantly associated with atorvastatin, HDL-C, TC, TG, LDL, CRP, IL-6, and TNF-α.

Conclusion

Atorvastatin can regulate lipid metabolism and reduce inflammatory cytokine levels and carotid atherosclerosis in patients with type 2 diabetes mellitus.

表1 2组2型糖尿病患者一般临床资料比较
表2 2组患者治疗前后血清糖代谢及胰岛素抵抗指标比较(±s
表3 2组患者治疗前后血清脂质水平比较(mmol/L,±s
表4 2组患者治疗前后相关炎性因子指标比较(±s)
表5 2组患者治疗前后颈动脉相关指标比较(±s)
表6 IMT影响因素的多元回归分析结果
[1]
Bianchi C, Miccoli R, Penno G, et al. Primary prevention of cardiovascular disease in people with dysglycemia [J]. Diabetes Care, 2008, 31 Suppl 2: S208-214.
[2]
Ko GT, Chow CC, Leung G, et al. High rate of increased carotid intima-media thickness and atherosclerotic plaques in Chinese asymptomatic subjects with central obesity[J]. Int J Cardiovasc Imaging, 2011, 27(6): 833-841.
[3]
Loughrey BV, McGinty A, Young IS, et al. Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial [J]. Clin Endocrinol (Oxf), 2013, 79(6): 800-806.
[4]
Zamani E, Mohammadbagheri M, Fallah M, et al. Atorvastatin attenuates ethanol-induced hepatotoxicity via antioxidant and anti-inflammatory mechanisms [J]. Res Pharm Sci, 2017, 12(4): 315-321.
[5]
Xu X, Gao W, Cheng S, et al. Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury [J]. J Neuroinflammation, 2017, 14(1): 167.
[6]
Zaccardi F, Pitocco D, Ghirlanda G. Glycemic risk factors of diabetic vascular complications: the role of glycemic variability [J]. Diabetes Metab Res Rev, 2009, 25(3): 199-207.
[7]
Malik S, Wong ND. Metabolic syndrome, cardiovascular risk and screening for subclinical atherosclerosis [J]. Expert Rev Cardiovasc Ther, 2009, 7(3): 273-280.
[8]
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials [J]. Lancet, 2010, 375(9716): 735-742.
[9]
金岩,韩锐,徐丹, 等. 阿托伐他汀治疗2型糖尿病的疗效及对C反应蛋白的影响 [J]. 中国医药指南, 2013, 11(30): 314-316.
[10]
Sena CM, Matafome P, Louro T, et al. Effects of atorvastatin and insulin in vascular dysfunction associated with type 2 diabetes [J]. Physiol Res, 2014, 63(2): 189-197.
[11]
Laakso M, Kuusisto J. Diabetes Secondary to Treatment with Statins [J]. Curr Diab Rep, 2017, 17(2): 10.
[12]
Feng B, Xu L, Wang H, et al. Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products [J]. Biochim Biophys Acta, 2011, 1812(9): 1130-1137.
[13]
Xu L, Zang P, Feng B, et al. Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats [J]. Diabetol Metab Syndr, 2014, 6(1): 102.
[14]
Nie P, Li D, Hu L, et al. Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors [J]. PLoS One, 2014, 9(5): e97009.
[15]
Gauberti M, Montagne A, Marcos-Contreras OA, et al. Ultra-sensitive molecular MRI of vascular cell adhesion molecule-1 reveals a dynamic inflammatory penumbra after strokes [J]. Stroke, 2013, 44(7): 1988-1996.
[16]
Tehrani S, Mobarrez F, Antovic A, et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia [J]. Thromb Res, 2010, 126(3): e225-231.
[17]
Meeuwisse-Pasterkamp SH, van der Klauw MM, Wolffenbuttel BH. Type 2 diabetes mellitus: prevention of macrovascular complications [J]. Expert Rev Cardiovasc Ther, 2008, 6(3): 323-341.
[18]
雷海,程改存,陆鹏, 等. 阿托伐他汀治疗2型糖尿病合并颈动脉粥样硬化的疗效观察 [J]. 现代医学, 2010, 38(4): 387-389.
[19]
崔维,王龙安,原霞. 彩色多普勒诊断仪评估阿托伐他汀对2型糖尿病患者颈动脉粥样硬化斑块的影响 [J]. 中国实用神经疾病杂志, 2014, 17(7): 110-111.
[1] 曹雯佳, 刘学兵, 罗安果, 钟释敏, 邓岚, 王玉琳, 李赵欢. 超声矢量血流成像对2型糖尿病患者颈动脉壁剪切应力的研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 709-717.
[2] 孟令凯, 李大勇, 王宁, 王桂明, 张炳南, 李若彤, 潘立峰. 袖状胃切除术对肥胖伴2型糖尿病大鼠的作用及机制研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 638-642.
[3] 李猛, 姜腊, 董磊, 吴情, 贾犇黎. 腹腔镜胃袖状切除术治疗肥胖合并2型糖尿病及脂肪胰的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 554-557.
[4] 刘盾, 潘晟. 不同入路腹腔镜袖状胃切除术用于肥胖症合并2型糖尿病的效果[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 150-154.
[5] 赵帅, 王伟, 李瑞奇, 周家杰, 王道荣. 3D腹腔镜下袖状胃切除术治疗肥胖合并2型糖尿病的临床疗效及影响因素分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 146-149.
[6] 陆文琪, 赵艳茹, 李焕娣, 樊欣娜, 王佳, 李萍. 2型糖尿病患者血清SMAD2和SOX6表达及其与蛋白尿的关系[J/OL]. 中华肾病研究电子杂志, 2024, 13(03): 145-151.
[7] 林庆喜, 曾钦霖, 谢琛璠, 魏梁锋. 封闭式钻孔引流联合阿托伐他汀治疗慢性硬膜下血肿的疗效观察[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(02): 91-96.
[8] 王星, 陈园, 热孜万古丽·乌斯曼, 郭艳英. T2DM、Obesity、NASH、PCOS共同致病因素相关的分子机制[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 481-490.
[9] 王璇, 娜扎开提·尼加提, 雒洋洋, 蒋升. 皮肤晚期糖基化终末产物浓度与2型糖尿病微血管并发症的相关性[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 447-454.
[10] 孙秀芹, 高美娟, 张琼阁, 吕凯敏, 王宏宇. 京西地区无心血管病史2型糖尿病中老年人群患心血管疾病的危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(03): 245-252.
[11] 孙琳, 韩萍萍, 张碧琳, 张军霞. 血清WISP1水平与2型糖尿病患者血尿酸升高的相关性[J/OL]. 中华临床医师杂志(电子版), 2024, 18(02): 178-182.
[12] 吴晓明, 翟仰魁, 王娟, 张硕, 许杰, 潘从清. 男性2 型糖尿病患者空腹C 肽和定量胰岛素敏感性检测指数与血浆致动脉粥样硬化指数的相关性[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(04): 288-294.
[13] 吴子龙, 吴冰, 袁开盛, 胡瑞翔, 杨华, 王存川. 肥胖与胰腺疾病研究进展[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(03): 213-219.
[14] 张梅, 陈卉, 李转霞, 王瑞, 李林娟. Metrnl和NLRP3炎症小体:糖尿病肾病的潜在诊断标志物[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(03): 193-199.
[15] 崔磊, 徐东升. 减重手术治疗肥胖患者胰岛素抵抗的研究进展[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 127-132.
阅读次数
全文


摘要